Related references
Note: Only part of the references are listed.Remdesivir, on the road to DisCoVeRy
Iwein Gyselinck et al.
LANCET INFECTIOUS DISEASES (2022)
The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp
Arun Bahadur Gurung et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2021)
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer et al.
NATURE MEDICINE (2021)
Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture
Khushboo Bafna et al.
CELL REPORTS (2021)
Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir
Ho Sing Lo et al.
ACS CENTRAL SCIENCE (2021)
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
Karen A. Gammeltoft et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
Marco Falcone et al.
INFECTIOUS DISEASES AND THERAPY (2021)
A novel coronavirus outbreak of global health concern
Chen Wang et al.
LANCET (2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan et al.
NATURE COMMUNICATIONS (2020)
Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2
Ren-Di Jiang et al.
CELL (2020)
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse et al.
NATURE (2020)
Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study
Faezeh Sadat Hosseini et al.
LIFE SCIENCES (2020)
An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
Alfonso Trezza et al.
SCIENTIFIC REPORTS (2020)
Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
Sivi Ouwerkerk-Mahadevan et al.
CLINICAL PHARMACOKINETICS (2016)
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants
Thierry Verbinnen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
Asa Rosenquist et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)